Literature DB >> 20920599

Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.

Javier Molina-Infante1, Lucia Ferrando-Lamana, Cristina Ripoll, Moises Hernandez-Alonso, Jose M Mateos, Miguel Fernandez-Bermejo, Carmen Dueñas, Nuria Fernandez-Gonzalez, Eva M Quintana, Maria Angeles Gonzalez-Nuñez.   

Abstract

BACKGROUND & AIMS: Despite consensus recommendations, eosinophilic esophagitis (EoE) is commonly diagnosed upon esophageal eosinophilic infiltration (EEI; based on ≥ 15 eosinophils per high power field; eo/HPF). We evaluated the prevalence of EEI before and after proton pump inhibitor (PPI) therapy and assessed the accuracy of EEI and pH monitoring analyses.
METHODS: Biopsies were taken from the upper-middle esophagus of 712 adults with upper gastrointestinal symptoms who were referred for endoscopy due to upper gastrointestinal symptoms. Patients with EEI were treated with rabeprazole (20 mg, twice daily) for 2 months. EoE was defined by persistent symptoms and >15 eo/HPF following PPI therapy.
RESULTS: Thirty-five patients (4.9%) had EEI, of whom 55% had a history of allergies, and 70% had food impaction or dysphagia as their primary complaint. Twenty-six EEI patients (75%) achieved clinicopathological remission with PPI therapy; of these, 17 had GERD-like profile (EEI <35 eo/HPF and objective evidence of reflux, based on endoscopy or pH monitoring), and 9 had EoE-like profile (EEI 35-165 eo/HPF, typical EoE symptoms and endoscopic findings). The PPI response was 50% in the EoE-like profile patients. The PPI-response was 50% in EoE-like profile patients. Likewise, PPI-responsive EEI occurred with normal (33%) and pathologic (80%) pH monitoring. Higher histologic cut-off values improved specificity and positive predictive for EoE (35%-35% for >20 eo/HPF; 46%-39% for >24 eo/HPF; 65%-50% for 35 eo/HPF).
CONCLUSIONS: In adults with EEI, 75% of unselected patients and 50% with an EoE phenotype respond to PPI therapy; pH monitoring is poorly predictive of response. Patients with PPI-responsive EEI >35 eo/HPF are phenotypically undistinguishable from EoE patients. EoE might be overestimated without clinical and pathologic follow-up of patient response to PPI.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920599     DOI: 10.1016/j.cgh.2010.09.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  115 in total

Review 1.  Diagnosis and management of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 11.382

2.  Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis.

Authors:  Evan S Dellon; Xiaoxin Chen; C Ryan Miller; John T Woosley; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

Review 3.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

Review 4.  Eosinophilic Esophagitis.

Authors:  Glenn T Furuta; David A Katzka
Journal:  N Engl J Med       Date:  2015-10-22       Impact factor: 91.245

5.  Development and validation of a registry-based definition of eosinophilic esophagitis in Denmark.

Authors:  Evan S Dellon; Rune Erichsen; Lars Pedersen; Nicholas J Shaheen; John A Baron; Henrik T Sørensen; Mogens Vyberg
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

6.  Effect of proton pump inhibitor on esophageal eosinophilia.

Authors:  Shauna Schroeder; Kelley E Capocelli; Joanne C Masterson; Rachel Harris; Cheryl Protheroe; James J Lee; Glenn T Furuta
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-02       Impact factor: 2.839

7.  Administrative coding is specific, but not sensitive, for identifying eosinophilic esophagitis.

Authors:  D A Rybnicek; K E Hathorn; E R Pfaff; W J Bulsiewicz; N J Shaheen; E S Dellon
Journal:  Dis Esophagus       Date:  2013-11-12       Impact factor: 3.429

8.  Epidemiology of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Gastroenterol Clin North Am       Date:  2014-03-19       Impact factor: 3.806

9.  Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.

Authors:  Edaire Cheng; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

Review 10.  Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.

Authors:  Mery Munoz-Persy; Alfredo J Lucendo
Journal:  Eur J Pediatr       Date:  2018-03-17       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.